Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

VaxOnco to sponsor phase I trial of Mayo Clinic cancer vaccine

July 27, 2011

Aeterna Zentaris reports nonclinical milestone for oral prostate cancer vaccine

July 22, 2011

Cel-Sci and Teva Pharmaceutical extend Multikine licensing agreement

July 20, 2011

Amgen gains European marketing approval for Xgeva

July 18, 2011

Enrollment complete in first cohort of Advaxis' phase II ADXS-HPV study

July 13, 2011

Merck KGaA to discontinue development of Toll-like receptor 9 agonist IMO-2055

July 8, 2011

Bristol-Myers Squibb and Innate Pharma enter global agreement for IPH-2102

July 8, 2011

Johns Hopkins University and Innogene Kalbiotech begin trial for lung cancer vaccine

July 8, 2011

Amgen submits sBLA to expand Xgeva indication to reduce risk of bone metastasis in prostate cancer

July 7, 2011

FDA grants Advaxis pre-IND meeting for prostate cancer immunotherapy Advaxis PSA

July 5, 2011

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...